In 2025, total Russian spending on drugs used for varicose veins increased by 13.2% and exceeded RUB 37 billion (at retail prices, including VAT). Unlike monetary sales volume, physical consumption continues to decline. Last year, 52.3 million packages of such drugs were sold at retail, with physical demand for phlebotonics decreasing by 3% over the year, compared to a decline of 1.2% the previous year.

According to the "Retail Audit of Drug Sales in Russia (total sell out)" from the analytical company RNC Pharma, systemic phlebotonic drugs dominate the retail market, accounting for 73% of the market's value, although their physical share does not exceed 42%. However, physical demand indicators for both groups showed negative dynamics last year. The beginning of 2026 was also accompanied by a decline in consumption — compared to January–February 2025, demand for phlebotonics in packages fell by 8%, while ruble growth was extremely modest at +3.6%.

Among phlebotonic manufacturers in the retail market, the Servier Group remains the undisputed leader, controlling approximately 33% of the category's monetary volume, a share that has remained virtually unchanged for several years. In this category, the company markets two brands, the main volume of which comes from the systemic drug Detralex (a combination of hesperidin and diosmin). This product is the absolute leader among all brands in pharmaceutical retail. In 2025, consumers spent over RUB 11.7 billion on this drug, with sales dynamics reaching +13.2% in rubles and +12.3% in packages. It is worth noting the high competition in this segment, with 17 direct INN analogues currently available. Nevertheless, the category continues to expand — total revenue from the sale of these drugs increased by 13.3%, with physical sales volume up by 5.7%.

Second place in the company ranking is occupied by Teva with a 15.2% ruble share, whose key drug in this group remains Troxevasin, available in both topical and systemic forms. The sales dynamics for this company's products last year were recorded at +9% in rubles. Domestic company Binnopharm retains third place in the ranking; in 2025, its products accounted for 14.5% of monetary sales in the group, with ruble growth of approximately 8% over the year, while physical consumption decreased by 9.5%. The losses are mainly associated with sales of the drug Angiorus, whereas demand for Venarus remained quite stable last year.

Among the TOP-10 manufacturers, the leader in growth rates was Artelar: in 2025, its revenue increased by 76%, with sales in packages up by 52%. This result was driven by a single brand in its portfolio — the tablet drug Roklis (INN hesperidin + diosmin). Ozon Pharmacevtika also showed notable dynamics, thanks to a wide portfolio of systemic and topical phlebotonics; the company increased sales by an average of 30% in both monetary and physical terms.

Outside the top tier, the highest sales growth in the category was shown by Uralbiopharm and Pharmvilar. Compared to 2024, the ruble sales volume of these companies increased 7.6-fold and 5.1-fold, respectively. In the first case, the growth was driven by Ascorutin; in the second, by Venatabs (INN hesperidin + diosmin).

Table. TOP-10 Manufacturing Corporations of Topical and Systemic Drugs Used for Varicose Veins by Monetary Sales Volume on the Russian Retail Pharmaceutical Market in 2025

[1] C05C — systemic drugs for varicose veins and C05B — topical drugs for varicose veins, according to the EphMRA classification